THERMO FISHER SCIENTIFIC INC.
TMONYSELatest results at a glance
Insights from the latest company results and reports · filed 23 Jul 2026
Quarterly Revenue and EPS Growth
Second quarter 2026 revenue increased 10% to $11.99 billion, with organic revenue growth of 5%. GAAP diluted EPS rose 9% to $4.68, while adjusted EPS grew 13% to $6.03.
Earnings Exceed Consensus Estimates
Reported adjusted EPS of $6.03 per share surpassed the same-quarter consensus estimate of $5.71 per share. The company has exceeded its quarterly consensus EPS estimates in each of the four most recent comparable quarters.
Operating Margin Expansion
GAAP operating income reached $2.09 billion, a 14% increase year-over-year, lifting the GAAP operating margin to 17.4% from 16.9%. Adjusted operating income rose 15% to $2.73 billion, expanding the adjusted operating margin to 22.8% from 21.9%.
Cash Flow and Capital Returns
Free cash flow of $6.293 billion in the fiscal year ended 2025-12-31 was 2.10 times the $3 billion in common-stock repurchases.
Product Launches and Collaborations
[2026-09-29] Thermo Fisher Scientific announced the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media for biologics and biosimilars development. [2026-09-29] The company also established a reseller agreement to distribute Evosep’s Eno separation platform and expanded involvement in molecular residual disease programs.
Company research evidence
Checked financial measurements with the values, reporting periods and measurement basis shown together. This evidence is available independently of the AI report.
Loading evidence…
Deep Dive Research
Source-linked company research for TMO
Revenue segmentation
Loading segment disclosures…